Loading...
Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer
BACKGROUND: The KRAS mutation is the driving force of pancreatic ductal adenocarcinoma (PDAC). Downstream effectors of KRAS signal pathways are crucial to the development of PDAC. The purpose of this study was to investigate the relationship between KRAS mutation and transgelin-2. Transgelin-2 is hi...
Na minha lista:
| Udgivet i: | J Exp Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6056937/ https://ncbi.nlm.nih.gov/pubmed/30041673 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-018-0818-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|